Cargando…
IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design
Rodent monoclonal antibodies with specificity towards important biological targets are developed for therapeutic use by a process of humanisation. This process involves the creation of molecules, which retain the specificity of the rodent antibody but contain predominantly human coding sequence. Her...
Autores principales: | Stoyle, Chloe L., Stephens, Paul E., Humphreys, David P., Heywood, Sam, Cain, Katharine, Bulleid, Neil J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590090/ https://www.ncbi.nlm.nih.gov/pubmed/28784690 http://dx.doi.org/10.1042/BCJ20170342 |
Ejemplares similares
-
Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development
por: Dumet, Christophe, et al.
Publicado: (2019) -
Bringing the Heavy Chain to Light: Creating a Symmetric, Bivalent IgG-Like Bispecific
por: Ramasubramanian, Anusuya, et al.
Publicado: (2020) -
Efficient N-Glycosylation of the Heavy Chain Tailpiece Promotes the Formation of Plant-Produced Dimeric IgA
por: Göritzer, Kathrin, et al.
Publicado: (2020) -
Genetic Removal of the CH1 Exon Enables the Production of Heavy Chain-Only IgG in Mice
por: Zhang, Tianyi, et al.
Publicado: (2018) -
Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells
por: Joshi, Kamal Kishore, et al.
Publicado: (2019)